Interindividual heterogeneity affects the outcome of human cardiac tissue decellularization by Tenreiro, Miguel F. et al.
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:20834  | https://doi.org/10.1038/s41598-021-00226-5
www.nature.com/scientificreports
Interindividual heterogeneity 
affects the outcome of human 
cardiac tissue decellularization
Miguel F. Tenreiro1,2, Henrique V. Almeida1,2, Tomás Calmeiro3, Elvira Fortunato3, 
Lino Ferreira4,5, Paula M. Alves1,2 & Margarida Serra1,2*
The extracellular matrix (ECM) of engineered human cardiac tissues corresponds to simplistic 
biomaterials that allow tissue assembly, or animal derived off-the-shelf non-cardiac specific matrices. 
Decellularized ECM from human cardiac tissue could provide a means to improve the mimicry of 
engineered human cardiac tissues. Decellularization of cardiac tissue samples using immersion-
based methods can produce acceptable cardiac ECM scaffolds; however, these protocols are mostly 
described for animal tissue preparations. We have tested four methods to decellularize human cardiac 
tissue and evaluated their efficiency in terms of cell removal and preservation of key ECM components, 
such as collagens and sulfated glycosaminoglycans. Extended exposure to decellularization agents, 
namely sodium dodecyl sulfate and Triton-X-100, was needed to significantly remove DNA content 
by approximately 93% in all human donors. However, the biochemical composition of decellularized 
tissue is affected, and the preservation of ECM architecture is donor dependent. Our results indicate 
that standardization of decellularization protocols for human tissue is likely unfeasible, and a 
compromise between cell removal and ECM preservation must be established in accordance with 
the scaffold’s intended application. Notwithstanding, decellularized human cardiac ECM supported 
human induced pluripotent-derived cardiomyocyte (hiPSC-CM) attachment and retention for up to 
2 weeks of culture, and promoted cell alignment and contraction, providing evidence it could be a 
valuable tool for cardiac tissue engineering.
Engineering biomimetic cardiac tissue is still challenging, and even the most promising approaches reported to 
date fail to integrate all the key components present in the cardiac niche, namely a sufficiently complex extracellu-
lar matrix (ECM). These engineered tissues often rely on biomaterials for tissue  assembly1, but such biomaterials 
are either simplistic compared to the ECM (e.g., single-protein matrices with collagen or fibronectin), have little 
or no presence in vivo (e.g., fibrin or synthetic polymers), bear batch-to-batch variability (e.g., Matrigel®), and are 
often from animal origin (e.g., rat-tail collagen, porcine gelatin or Matrigel®). Even though bioartificial cardiac tis-
sues are promising platforms to expedite drug development, their use as reliable disease models merits improve-
ments as the cardiac ECM plays a critical role in several cardiac pathologies, such as myocardium infarction and 
progression into heart  failure2. Alternative sources to cardiac ECM with clearance for medical applications are 
mostly from animal origin, such as porcine small intestine submucosa (SIS) and porcine urinary bladder  matrix3. 
Lack of cardiac specificity of alternative ECM sources has shown to influence embryonic stem cell differentiation 
towards  cardiomyocytes4. This may be due to a differential ECM biochemical profile and architecture between 
tissues/organs, that ultimately affects stem cell fate and optimal cell function. Naturally derived animal cardiac 
ECM can improve these shortcomings and has shown to contribute to superior cardiomyocyte  performance4,5. 
Nonetheless, human-specific features of cardiac ECM might be lacking in products from animal origin, and so 
a human derived biomaterial could, in principle, more closely resemble the cardiac microenvironment, besides 
circumventing issues related with xenogenecity.
Decellularization is the standard methodology to obtain an ECM scaffold from tissues and organs, in which 
ideally all the cellular components and genetic material are removed, leaving a preserved natural scaffolding 
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biomaterial with a native architecture suitable for tissue/organ bioengineering. Most studies rely on whole-
heart decellularization to obtain cardiac ECM, that uses perfusion through the organ vasculature to infuse in 
a stepwise manner the decellularization solutions (typically chemical or enzymatic)6–8. Initial studies showed 
that anterograde coronary perfusion with 1% of the ionic detergent sodium dodecyl sulfate (SDS) for 12 h was 
sufficient to fully decellularize a rat  heart6; however, if detergent time is kept constant (12 h), decellularizing a 
porcine heart requires 4%  SDS9, otherwise longer periods of SDS exposure (at 1%) are required, as it is the case 
of the human heart (192 h)8. Therefore, inter-species differences, including recognizable sizing variations, are 
likely to compromise direct translation of successful protocols optimized in animals for human use. Furthermore, 
perfusion-based decellularization protocols are suitable to decellularize postmortem hearts unfit for transplanta-
tion but difficult to use accurately to decellularize tissue samples from cardiac biopsies, that are also more easily 
obtained from human donors undertaking interventional surgery. These tissue samples can be decellularized with 
the same decellularization agents using agitation instead, but established protocols in small or large animals may 
prove difficult to adapt to human tissue without additional  modifications10,11. Besides customization of decel-
lularization protocols for human usage, the heterogeneity between donors might prevent their standardization. 
In fact, decellularizing human liver discs with a protocol optimized for porcine liver decellularization was only 
successful for one donor, with the other four showing different levels of remaining cells and  matrix12.
In this work, we evaluated how effective these previous protocols are to decellularize human cardiac tissue in 
three unrelated human donor samples and assessed the suitability of the decellularized scaffold to support the 
culture of cardiomyocytes derived from human induced pluripotent stem cells for application in cardiac tissue 
bioengineering.
Materials and methods
Decellularization of human cardiac tissue. Heart tissues were harvested from donor human hearts that 
were not suitable for transplantation at the Coimbra Hospital and University Centre (CHUC, Coimbra, Portu-
gal), after informed consent was obtained from all patients and in accordance with the regulations of tissue bank 
and the approval of the Ethics Committee of Medical School of the University of Coimbra (CE-022/2017). All 
methods in this study involving human heart tissue were carried out in accordance with relevant guidelines and 
regulations. Donor data and tissue experimental allocation are outlined in Table 1.
Soon after harvest, tissue samples were stored at − 80 °C and kept there until usage. Myocardial tissue samples 
were thawed and cut into pieces of about 1 mm in thickness, as previously  described10,11. The following decellu-
larization methods were modified from already published protocols to assess their applicability for human tissue. 
For each method tissue pieces were decellularized with the following succession of solutions: Method A) 10 mM 
Tris (Calbiochem), 5 mM ethylenediamine tetraacetic acid (EDTA, Sigma-Aldrich), pH 7 for 2 h (lysis buffer); 
0.5% wt/vol SDS (Sigma-Aldrich) in Dulbecco’s phosphate-buffered saline (DPBS, Thermo Fisher Scientific) for 
6 h; DPBS overnight; fetal bovine serum (FBS) for 3 h at 37 °C (serum DNAase activity can aid the removal of 
nucleic acids before  rinsing13); DPBS for 24 h (modified  from14); Method B) 1% wt/vol SDS in DPBS for 48 h; 
1% vol/vol Triton-X-100 (Sigma-Aldrich) in DPBS for 30 min; DPBS for 24 h (modified  from10); Method C) 
10 mM Tris, 5 mM EDTA, pH 7 for 24 h (lysis buffer); 1% wt/vol SDS in DPBS for 48 h; 1% vol/vol Triton-X-100 
in DPBS for 30 min; DPBS for 24 h; Method D) 1% wt/vol SDS in DPBS for 192 h; 1% vol/vol Triton-X-100 in 
DPBS for 24 h; DPBS for 24 h (modified  from8). Each step in all methods was performed at room temperature 
(RT, 20–25 °C), if not stated otherwise, under constant orbital agitation to aid reagent diffusion into the tissue. 
Gross tissue morphology was imaged in a stereo microscope (DMIRB, Leica).
Histology and Nuclei fluorescent staining. Tissue pieces were fixed with 4% wt/vol buffered paraform-
aldehyde overnight, paraffin embedded and sectioned (3 μm thickness) on a rotary microtome (RM 2135, Leica). 
After deparaffinization, samples were stained with Hematoxylin & Eosin (H&E) (Sigma-Aldrich), Masson Tri-
chrome with Aniline Blue (IHC World), Picro Sirius Red (Polysciences) and Alcian Blue (Polysciences), accord-
ing to the manufacturer’s instructions. Histological images were digitalized in a NanoZoomer SQ whole slide 
scanner (Hamamatsu Photonics) and viewed with NDP.view open-source software (NDP.view v.2.7.43, Hama-
matsu Photonics). Cell alignment was measured with the FibrilTool Fiji  plugin15, and the mean angular orienta-
tion for each cell-containing ROI was computed across several histological micrographs. Density histograms 
were generated in R (v.4.0.3) using the ggplot2 package (v.3.3.3) with a bin of 2°. For  nuclei staining microscopy 
Table 1.  Cardiac tissue donor data. LV left ventricle, hiPSC-CM human induced pluripotent cardiomyocytes.
Characteristics Donor 1 Donor 2 Donor 3 Donor 4
Age 69 67 67 61
Sex Male Female Female Male
Cause of death Intracerebral hemorrhage Not disclosed Not disclosed Not disclosed
Reason for exclusion from trans-
plantation Not disclosed Not disclosed Not disclosed Not disclosed
Tissue source Myocardium, LV; No pathology associated
Myocardium Apex, LV; No pathol-
ogy associated
Myocardium, LV; No pathology 
associated
Myocardium, LV; No pathology 
associated
Experimental allocation Evaluation of decellularization protocols
Evaluation of decellularization 
protocols
Evaluation of decellularization 
protocols
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analysis, deparaffinized samples were mounted in ProLong™ Gold antifade reagent containing 4′,6′-diamino-
2-fenil-indol (DAPI) (Life Technologies).  Samples were viewed in a fluorescence microscope (DMI600, Leica) 
and DAPI-stained nuclei were quantified in  Fiji15. The number of nuclei counts were normalized to ROI area.
Biochemical analysis of cardiac extracellular matrix. Biochemical characterization of cardiac ECM 
was carried out as previously  described16. Decellularized samples were digested in 500 μL of papain solution 
(125 μg   mL−1 papain in 0.1 M sodium acetate, 5 mM cysteine-HCl, 0.05 M EDTA, pH 6.0, all from Sigma-
Aldrich) for 20 h at 60 °C under agitation. Native tissue samples with comparable wet weight were also digested 
to serve as controls. The dsDNA content was determined using the Quanti-iTTM PicoGreen™ assay (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. The fluorescent intensity was measured in the 
microplate reader Infinite®200 PRO NanoQuant (TECAN). The sulfate glycosaminoglycan (s-GAG) content was 
quantified using the 1,9-dimethylmethylene blue assay (Glycosaminoglycan Assay Blyscan™, Biocolor) and col-
lagen content (soluble and insoluble) was determined via the hydroxyproline assay (Sircol™ Collagen Assay, 
Biocolor), according to the manufacturer’s instructions. Sample absorbance was measured in the microplate 
reader Infinite®200 PRO NanoQuant at the corresponding ECM component wavelength. Data was expressed as 
the measured component mass normalized to tissue wet weight.
Scanning electron microscopy. Tissue samples were fixed with 2.5% vol/vol buffered glutaraldehyde 
(Sigma-Aldrich), for 2 h at room temperature. Fixed tissue was washed in DPBS (three times: 5–10 min each) 
and dehydrated with a series of ethanol solutions, starting with 50% vol/vol and progressing through 70%, 80%, 
95% and 100% absolute ethanol. Samples were dried in adhesive carbon tabs (12 mm, Agar Scientific), sputter-
coated with a 15 nm Au/Pd film and visualized in a Hitachi TM3030Plus tabletop scanning electron microscope 
operated in BSE mode at an accelerating voltage of 15 keV. The alignment of ECM fibers was measured with the 
FibrilTool Fiji plugin. In brief, the mean fiber orientation direction and anisotropy index (0—random align-
ment/isotropic array, 1—perfect alignment/purely anisotropic array) were computed for each ROI and across 
several photomicrographs. Density histograms were generated in R (v.4.0.3) using the ggplot2 package (v.3.3.3) 
with a bin of 15°.
hiPSC culture and differentiation towards cardiomyocytes. hiPSC line DF19-9-11 T.H (WiCell, 
Madison, WI) was used in this study. hiPSC were expanded on Matrigel® (Corning) coated plates in mTeSR1 
medium (STEMCELL Technologies) at 37 °C, in a humidified atmosphere of 5%  CO2. The culture medium was 
exchanged daily and cells were routinely passaged when reaching 80% confluence using Versene (Thermo Fisher 
Scientific). Differentiation of hiPSC into cardiomyocytes (hiPSC-CM) was induced when cell confluence reached 
90%, as previously  reported17,18. Briefly, at day 0 of differentiation, expansion medium was replaced by RPMI 
medium (Thermo Fisher Scientific) supplemented with B27 without insulin (RPMI/B27 minus ins., Thermo 
Fisher Scientific), 80 ng/mL activin A (PeproTec), and 50 mg/mL ascorbic acid (Sigma–Aldrich). After 24 h, 
spent medium was changed for fresh RPMI/B27 minus ins. supplemented with 5 µM IWR-1 (Sigma–Aldrich) 
and 50 µg/mL ascorbic acid (Sigma–Aldrich). At day 3 (72 h after induction), spent medium was exchanged for 
fresh RPMI/B27 minus ins. supplemented with 5 µM IWR-1. Spontaneous beating generally started by day 7 of 
differentiation.
Recellularization of decellularized ECM with hiPSC-CM. Decellularized cardiac tissue pieces were 
immobilized on Poly-l-Ornithine (Sigma–Aldrich) coated coverslips placed on 24-well plates. Briefly, 500 µL of 
a 16% vol/vol Poly-l-Ornithine solution in DPBS−/− (Thermo Fisher Scientific) was added on top of each cover-
slip for 3 h and afterwards each well was washed twice with DPBS−/−. Coated plates were left at 4 °C overnight. 
Decellularized tissue pieces were placed on top of each coverslip for immobilization and washed thrice with 70% 
vol/vol ethanol for 15 min, followed by UV sterilization in aseptic conditions for 20 min.
Contracting hiPSC-CM monolayers were dissociated by incubation with TrypLE™ Select (Thermo Fisher 
Scientific) for 5 min at 37 °C, added to culture medium (RPMI/B27 minus ins.), centrifuged at 220×g for 5 min, 
and then used to recellularize tissue scaffolds decellularized through method D. hiPSC-CM (1.25 ×  106 cells) were 
seeded onto each scaffold in a suspension volume of 40 µL under static conditions. After 30 min the tissue was 
immersed in RPMI medium supplemented with B27 with insulin (RPMI/B27 plus ins., Thermo Fisher Scientific). 
Medium was changed every 3 days for a total of 14 days of culture.
Immunofluorescence of recellularized cardiac tissue. Recellularized cardiac tissue was collected 
from culture and fixed in 4% wt/vol paraformaldehyde with 4% wt/vol sucrose in DPBS for 20 min at RT. Sam-
ples were dehydrated in 30% wt/vol sucrose overnight at 4 °C, embedded in Tissue-Tek® O.C.T. (Sakura) and 
frozen at − 80 °C until use. The blocks of O.C.T. were then sliced with a thickness of 10 μm in a cryomicrotome 
(Cryostat CM 3050, Leica). Cryosections were allowed to dry at RT for 1 h, permeabilized with 0.1% wt/vol 
Triton X-100 solution in DPBS and blocked with 0.2% wt/vol Fish Skin Gelatin in DPBS solution (hereafter 
designated as blocking buffer solution) for 30 min at RT. Primary antibodies (cardiac troponin T, Thermo Fisher 
Scientific, 1:200) were incubated overnight at 4 °C and secondary antibodies (goat anti–mouse AlexaFluor 488, 
Thermo Fisher Scientific, 1:500) were incubated for 1 h at RT, both diluted in blocking buffer solution. Samples 
were mounted with ProLong™ Gold antifade reagent containing DAPI and visualized using a confocal micro-
scope (SP5 Live, Leica).
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Statistics. Data are presented as mean ± standard deviation (SD). Raw data were tested for normality of dis-
tribution using the Shapiro–Wilk normality test, and statistical analyses were performed using unpaired t-tests 
(two-tailed), Kruskal–Wallis tests with Dunnett’s multiple-comparison test or one-way ANOVA tests with Tuk-
ey’s multiple comparison test. GraphPad Prism version 7.0a was used for statistical analyses.
Results
Differences in human cardiac tissue decellularization outcome across protocol and donor. In 
this study, we tested four methods to develop an appropriate protocol for human cardiac tissue decellularization 
(Fig. 1a) and evaluated their efficiency in three unrelated donors (1, 2 and 3; Table 1). Histological staining using 
H&E and Masson’s Trichrome allowed preliminary assessment of the impact of all decellularization strategies 
tested concerning loss of cellularity as well as ECM structure and composition preservation (Fig. 1b–j).
Even though most decellularization methods for cardiac tissue are optimized either in small or large animals, 
we are aware of a protocol that was tested in human myocardial tissue samples. Method A was already reported 
for decellularization of micrometric sheets (~ 300 µm) of human myocardium biopsies and used a low percent-
age of SDS (0.5%) for 6 h followed by a washing step with  FBS14 (Fig. 1a). This method resulted in reduced 
removal of nuclei and overall maintenance of ECM proteins for the three donors, with limited disruption of 
tissue architecture (Fig. 1b–j, 2nd column). For human myocardium micrometric slices method A can yield an 
almost complete reduction in dsDNA  content14, however it became evident it was not efficient for attempting 
decellularization of tissue pieces with about 1 mm in thickness.
We next tested the applicability of protocols developed for porcine cardiac tissue decellularization on human 
samples, which typically work well for millimeter thick tissue pieces but require a more extended exposure 
and higher concentration of chemical agents to achieve complete  decellularization10,11 (i.e., Methods B and C, 
Fig. 1a). Method B used 1% SDS for 48 h and 1% Triton-X-100 for 30 min, and despite 2–3 days of exposure to 
decellularization agents being enough to remove cellular material from porcine cardiac tissue, the same did not 
hold for human tissue samples. In fact, donor-to-donor variability was observed when using method B; while 
for donor 1 there was an almost complete removal of cells and preservation of interstitial collagen matrix, for 
donors 2 and 3 method B was inefficient to remove the majority of cells, even though ECM architecture appeared 
more disorganized in comparison with method A (Fig. 1b–j, 3rd column). Incorporating an initial step to pro-
mote cell lysis can facilitate subsequent cellular membrane solubilization by detergents, as previously described 
for a multitude of other  tissues19. Thus, in method C cardiac tissue pieces were firstly treated with a lysis buffer 
solution for 24 h, and the remainder steps of the protocol were done similarly to method B (Fig. 1a). Method 
C yielded inconsistent decellularization outcomes among donors; no meaningful differences were observed for 
donor 1 and 3 when comparing method B and C, even though donor 2 showed a reduction in nuclei staining 
(Fig. 1b–j, 4th column).
Overall, a lysis step was not sufficient to achieve a similar decellularization outcome among cardiac tissue 
donors, and so we sought to instead extend the exposure to detergents. Method D was performed using the same 
concentrations of detergents as in method B, but tissue pieces were solubilized in SDS for 192 h (8 days) followed 
by 24 h in Triton-X-1008 (Fig. 1a). For donor 1, method D completely removed cellular material and yielded a 
decellularized scaffold with apparent preservation of ECM fibrous components. Comparatively to methods B 
and C, method D seems to have further reduced nuclei staining in donors 2 and 3. Even though there is a more 
noticeable staining for matrisome proteins, namely collagens, in decellularized tissue sections through method 
D for donors 2 and 3, partially unremoved cellular components are still showing (Fig. 1b–j, 5th column).
Characterization of decellularized extracellular matrix composition and architecture. To 
quantitatively assess the degree of decellularization, reminiscent double stranded DNA (dsDNA) was quanti-
fied. Native myocardial tissue contained 297.4 ± 135.5 ng/mg wet tissue of dsDNA, and only longer detergent 
treatment allowed a significant removal of almost all nucleic material; decellularized tissue through method D 
had 19.6 ± 16.7 ng/mg wet tissue of dsDNA, corresponding to a 93.4% reduction (Fig. 2a). Methods A, B and C 
yielded decellularization efficacies of 36.5% (188.8 ± 82.0 ng/mg wet tissue), 59.6% (114.4 ± 94.5 ng/mg wet tis-
sue) and 72.2% (82.7 ± 68.8 ng/mg wet tissue), respectively, and dsDNA content was not considered statistically 
significant from native tissue. Tissue sections decellularized through method D were stained with DAPI and 
revealed a significant reduction of nucleic material (Fig. 2b, c).
Biochemical analysis of decellularized tissue indicated moderate decreases of soluble and insoluble collagen, 
and low retention of s-GAGs (Fig. 2d), especially for method D. Picro Sirius Red staining for collagen (Fig. 2e, 
g, i) and Alcian Blue staining for GAGs (Fig. 2f, h, j) confirmed consistent reduction of these ECM components 
in all tissue donors for all strategies tested, even though they are still present in decellularized tissue sections 
obtained using method D.
Although method D can practically remove all nucleic material and moderately retains ECM components, 
tissues became softer after decellularization (Fig. 1b, e, h), which could indicate partial destruction of their 
microarchitecture. In fact, the 3D architecture of decellularized cardiac tissue was not preserved similarly among 
donors after decellularization using method D (Fig. 3). Typical anisotropic interconnected lacunae were absent 
in donor 1, but for the remaining tissue donors structural compliance did not seem to be affected (Fig. 3a). We 
examined the gross alignment of ECM fibers on native cardiac tissue and compared them to the decellularized 
cardiac tissue through method D. On native tissue there is a low dispersion of ECM fiber orientation, with the 
majority occupying two to three 15° bins in density histograms (Fig. 3b). However, the same tendency is only 
maintained for donors 2 and 3 after decellularization. The same trend is evident with the anisotropy index of 
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Figure 1.  Histological assessment of the different chemical-based decellularization methods attempted for 
human cardiac tissue. (a) Chemical-based decellularization methods tested for human cardiac tissue. The details 
regarding the solutions used and exposure duration applied are highlighted for each decellularization step. For 
each donor is shown: (b), (e), (h) Gross tissue morphology. Scale bars: 1 mm; (c), (f), (i) Hematoxylin & Eosin 
staining. Scale bars: 100 µm; (d), (g), (j) Masson’s Trichome staining. Scale bars: 100 µm.
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Figure 2.  Biological characterization of chemical-based decellularized human cardiac tissue. (a) Double 
stranded DNA (dsDNA) content of native and decellularized cardiac tissue for all methods, normalized to 
tissue wet weight (n = 3; one-way ANOVA, F4,10 = 4.38, *p < 0.05 with Tukey’s multiple comparison test). (b) 
Immunofluorescence of nuclei (DAPI, white) in native and decellularized tissue through method D for each 
donor. Scale bars: 50 µm. (c) Number of DAPI + nuclei per cross-section area (n = 3; two-tailed unpaired t-test, 
***p < 0.001). (d) Biochemical analysis for soluble collagen (n = 3; Kruskal–Wallis test, *p = 0.0229, *p < 0.05 with 
Dunnett’s multiple-comparison test), insoluble collagen (n = 3; one-way ANOVA, F4,10 = 2.304, following Tukey’s 
multiple comparison test), sulfated glycosaminoglycans (s-GAGs; n = 3; one-way ANOVA, F4,10 = 7.709, *p < 0.05 
and **p < 0.01 with Tukey’s multiple comparison test) on native and decellularized cardiac tissue for all methods, 
normalized to tissue wet weight. The average of the 3 cardiac tissue donors was used as a representative value for 
the component in the myocardium. (e), (g), (i) Picro Sirius Red (PSR) and (f), (h), (j) Alcian Blue staining on 
native and decellularized tissue for all methods. Scale bars: 100 µm. Data are represented as mean ± SD.
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Recellularization of decellularized cardiac tissue with hiPSC-cardiomyocytes. We then tested 
whether decellularized tissue through method D could support cell engraftment and tissue formation using car-
diomyocytes derived from human induced pluripotent stem cells (hiPSC-CM), that were generated via temporal 
modulation of the Wnt/β-catenin pathway, as we previously  described17,18. hiPSC-CM were seeded as single cells 
on decellularized tissue strips (~ 1 mm length, ~ 1 mm height) and cultured for an additional 2 weeks. These 
tissue strips supported hiPSC-CM attachment, ensuring efficient cell retention (Fig. 4a, b) and sustaining spon-
taneous contraction up to 14 days (Supplementary Video 1). Noteworthy, recellularized cardiac tissues showed 
positive staining for cardiac troponin T (Fig. 4c), confirming their cardiac phenotype. Furthermore, the decel-
lularized scaffold encouraged hiPSC-CM alignment within 14 days of in vitro culture, with a mean cell angular 
orientation closely approaching the values measured for ventricular cardiomyocytes in native cardiac muscle 
(Fig. 4d).
Discussion
Cardiac muscle is a structurally complex tissue optimized for life-long pumping function, and so it is challenging 
to replicate in vitro1. The ECM is nature’s template of a biomaterial and, through decellularization, such a scaffold 
could be produced to reliably engineer bioartificial cardiac tissue. Here, we aimed at evaluating several methods 
to efficiently decellularize human cardiac tissue, and test if the tissue scaffold could be used for tissue engineering.
Human cardiac tissue can be harvested during interventional biopsies or through segmental resection of 
postmortem hearts unsuitable for transplantation purposes. However, the vascular network of these tissue samples 
is often inaccessible, prohibiting perfusion of decellularization agents. In these cases, decellularization is often 
accomplished via tissue immersion in decellularization agents under gentle agitation to promote efficient diffu-
sion. Among the factors that need to be considered when using this approach is tissue thickness. This provides 
reasoning why Method A, that was implemented on micrometer thick myocardium  slices14, was ineffective to 
decellularize ~ 1 mm thick tissue pieces, that understandably have a higher cell density. An almost complete 
removal of nucleic material for all human cardiac tissues tested was only achieved in method D, in which the 
exposure times to detergents is practically equal to those used in whole-human heart perfusion-decellularization8. 
Lack of homogeneous exposure to decellularization solutions in methods using immersion is a clear limitation 
compared to perfusion-decellularization, and consequently prolonged exposure times are mandatory to eliminate 
dsDNA and other genetic material present in millimeter thick tissues. Even though mechanical damage to the 
ECM associated with pressure flow is minimal in immersion methods compared to perfusion-decellularization20, 
the need to extend detergent action in these methods undeniably influenced ECM biochemical composition. 
Quantitative analyses of some of the most prevalent ECM components, such as collagens and s-GAGs, revealed 
Figure 3.  Scanning electron microscopy analysis of native and decellularized human cardiac tissue. (a) 
Architecture of native cardiac tissue and the decellularized scaffold using method D. Scale bars: 50 µm. (b) 
Density histogram of extracellular matrix fiber orientation of native and decellularized tissue using method D 
(n = 35–55 ROI analyzed per condition per tissue donor). (c) Anisotropy index (0—random alignment/isotropic 
array, 1—perfect alignment/purely anisotropic array) of native and decellularized tissue using method D (n = 3; 
two-tailed unpaired t-test). Data are represented as mean ± SD.
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extended exposure to detergents significantly affected soluble collagen and s-GAG presence in decellularized 
tissue through method D. Others have also found out the retention of soluble components, such as s-GAGs21, 
soluble  collagen8,  elastin8 and growth  factors22, can be severely affected using SDS/Triton-X-100 combinations, 
especially with extended exposure times. Conversely, insoluble collagen, that is more mature and mechanically 
resilient owed to cross-linking, is better retained.
Interestingly, we observed high variability when assessing the efficiency of methods B and C. Method B was 
sufficient to substantially reduce tissue cellularity and dsDNA content in donor 1, but the same was not verified 
for donors 2 and 3. Method C was an attempt to improve method B without extending detergent exposure, but 
was insufficient to significantly reduce cellular content in donors 2 and 3. The 48 h SDS period was based on 
successful protocols optimized to decellularize porcine cardiac  tissue10. Inter-species differences may therefore 
prevent direct translation of protocols implemented in animals to human tissue. The reasons for such disparities 
may be manifold, in which tissue age may play a part. Human tissue samples are typically obtained from older 
donors, like the ones used here, while animal tissue can be harvested at earlier stages of life. Ageing induces struc-
tural changes in the myocardium, such as cardiomyocyte hypertrophic remodeling, increased collagen deposition 
and cross-linking, and increased proteolytic degradation via matrix metalloproteinase  activity23, that could well 
impact the efficiency of decellularization agents. Even among animals, it has been shown SIS-ECM harvested 
from pigs that differ only in age presented dissimilar mechanical, structural and biological  properties24. In addi-
tion, porcine and human cardiac ECM can simply have a distinct biological composition, and so be differentially 
susceptible to the type, concentration and exposure time of decellularization agents. For example, the higher 
lipidic content of decellularized human cardiac ECM when compared with its porcine analogue compromised 
in vitro gelation after  solubilization25.
We could have further evaluated a range of ionic detergent treatment between 2 and 8/9 days, aiming at iden-
tifying an optimal protocol less harsh than method D; however, such an alternative may not exist since dsDNA 
was still present (in low amounts) in donors 2 and 3 after method D. Instead, combining detergents with an 
endonuclease may be preferable to reduce detergent exposure, even though nucleases can persist in tissue after 
the rinsing  step19. Despite prolonged SDS/Triton-X-100 exposure being useful to reduced dsDNA to acceptable 
levels, we were unable to completely eliminate cellular components in donors 2 and 3 after method D (and to 
Figure 4.  Assessment of tissue formation capacity of human induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CM) on decellularized human cardiac tissue. (a) Hematoxylin & Eosin and (b) Masson’s 
Trichome staining of decellularized (method D) and recellularized tissue after 14 days of culture, at low (scale 
bars: 100 µm) and high magnification (scale bars: 50 µm). (c) Immunofluorescence micrograph of cardiac 
troponin T (cTNT, red) expression in decellularized tissue and recellularized tissue after 14 days of culture, 
and counterstained with DAPI (blue). Scale bar: 50 µm. (d) Density histogram of mean angular orientation of 
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a lesser extent in  donor 4; view Fig. 4b). The denaturant properties of these detergents seem to be efficient in 
solubilizing cell membranes, and consequently wash away nucleic material, but SDS action, in particular, was 
insufficient to effectively disrupt intracellular protein–protein interactions and aid their solubilization, regard-
less of cardiac tissue incubation with a lysis buffer solution beforehand (i.e., method C). In postmortem muscle 
tissue, as ATP is depleted, myosin heads remain bound to actin, indefinitely creating a rigor actomyosin complex 
that causes muscle tension and is challenging to properly  solubilize26. This could explain why cellular remnants 
persisted in donors 2 and 3 after method D, which are possibly derived from cardiomyocytes’ contractile appa-
ratus proteins and not from non-myocytes. In fact, attempting to decellularize mice left ventricle tissue with SDS 
alone created protein aggregates, that included macroproteins such as titin, and these were difficult to solubilize 
without enzymatic  digestion27. Replacing SDS/Triton-X-100 with a trypsin/Triton-X-100 combination showed 
to better eliminate cellular remnants during perfusion-decellularization of thick porcine cardiac tissue  slabs28. 
Nevertheless, others have reported trypsin has nonspecific degradation effects on heart ECM, particularly affect-
ing preservation of collagen IV, laminin and  elastin29. To overcome these issues, it has been proposed sarcolemma 
permeabilization followed by incubation with non-enzymatic solutions that allow sarcomere relaxation and disas-
sembly can effectively fully decellularize rat myocardium patches, outperforming SDS-based  methods30. Still, it 
remains elusive if the same protocol can be consistently applied to human tissue or whether it requires tuning.
Besides failure in using protocols established in animal tissue, human donor-to-donor variability is still 
apparent in our study. For donor 1, method B or C are suitable decellularization methods, showing successful 
removal of nucleic material and preservation of collagen content. However, when attempting to come up with 
a “one-size fits all” protocol (i.e., method D), the anisotropy of donor 1 was irreversibly lost alongside with 
noteworthy changes in its composition. For donors 2 and 3 tissue architecture was maintained and dsDNA 
significantly removed, yet tissue biochemical composition is thoroughly affected. Therefore, obtaining an acel-
lular scaffold from human cardiac tissue that is both sufficiently complex and presents minimal variability 
might require optimization of current methods in a personalized way. The interindividual heterogeneity across 
human cardiac tissue is surprising but not unexpected, as a previous study already confirmed, through a global 
proteomics analysis, human myocardial ECM preparations show significant donor-to-donor  variability31. The 
reasons behind this are challenging to discern and may be a combination of multiple factors like age, gender, and 
differential tissue cellular and molecular profiles, among others that warrant further investigation. Despite the 
low number of biological samples analyzed, our study reinforces the idea tissue-to-tissue variability should be 
considered when evaluating a decellularization protocol, which is often overlooked in the field. Furthermore, a 
compromise between cell removal and ECM preservation must be established, since for most strategies complete 
elimination of cells is incompatible with full retention of ECM  proteins29, and an acellular scaffold may not even 
be essential if the ECM is not intended for in vivo implantation.
We further confirmed the suitability of the decellularized scaffold for human myocardium bioengineer-
ing. Previous attempts at recellularizing cardiac ECM have either used animal-derived neonatal proliferative 
 cardiomyocytes6,7, non-cardiac  cells14,32 or human uncommitted cardiac progenitor  cells33. Fewer studies have 
used hiPSC-CM, and those that have attempted to recellularize human cardiac ECM with these cells have done 
it with low cell  densities8,14,34, impairing efficient cell retention and robust tissue formation. In this work, we 
were able to fully repopulate decellularized cardiac tissue with hiPSC-CM, and the scaffold ensured cell reten-
tion, alignment and sustained spontaneous contractions up to 2 weeks in culture. In two-dimensional planar 
culture conditions hiPSC-CM lack proper organization and are unable to replicate the bundle-like appearance 
of cardiac  muscle1. Immature neonatal cardiomyocytes are responsive to substrate stiffness, that influences 
twitch force and myofibril  structure35. Substrate stiffness equally tunes the mechanical output of hiPSC-CM, 
which is improved when it matches the physiological stiffness of the  myocardium36. Although further studies are 
needed, our decellularized human cardiac scaffold may be exerting a similar effect, thus improving the mechano-
microenvironment of hiPSC-CM, and possibly features of structural  maturation16.
Taken all together, producing an ECM preparation from human cardiac tissue requires a protocol tailored 
to the donor, with specific criteria outlining how biomimetically faithful the scaffold needs to be as to find a 
balance between acellularity and ECM compositional and architectural preservation. This perspective is in line 
with the goals of personalized medicine, ensuring product quality when designing an ECM biomaterial that is 
adequate for each experimental or clinical scenario. For tissue bioengineering applications we envision method 
D suffices; however, to study the cardiac ECM’s role during  differentiation4 or how an  aged37 or  diseased38 ECM 
contributes to alteration in cardiac phenotype, the harshness of method D might compromise product quality 
attributes and other decellularization strategies should be pursued. Despite how tempting the notion of protocol 
standardization is, for human tissue it is likely unfeasible.
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